Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalMarket CapitalizationReturn on AssetsReturn on Capital EmployedReturn on Equity

Spyre Therapeutics (SYRE) FCF Margin: 2015-2023

Historic FCF Margin for Spyre Therapeutics (SYRE) over the last 5 years, with Jun 2023 value amounting to -2,419.04%.

  • Spyre Therapeutics' FCF Margin rose 88864.00% to -2,419.04% in Q2 2023 from the same period last year, while for Jun 2023 it was -5,495.60%, marking a year-over-year decrease of 502295.00%. This contributed to the annual value of -11,276.52% for FY2023, which is 783376.00% down from last year.
  • Per Spyre Therapeutics' latest filing, its FCF Margin stood at -2,419.04% for Q2 2023, which was up 72.84% from -8,906.06% recorded in Q1 2023.
  • Over the past 5 years, Spyre Therapeutics' FCF Margin peaked at 17.10% during Q2 2021, and registered a low of -10,797.62% during Q4 2022.
  • Moreover, its 3-year median value for FCF Margin was -2,419.04% (2023), whereas its average is -4,075.09%.
  • Per our database at Business Quant, Spyre Therapeutics' FCF Margin slumped by 1,026,886bps in 2022 and then spiked by 88,864bps in 2023.
  • Over the past 3 years, Spyre Therapeutics' FCF Margin (Quarterly) stood at -528.76% in 2021, then crashed by 1,026,886bps to -10,797.62% in 2022, then spiked by 88,864bps to -2,419.04% in 2023.
  • Its last three reported values are -2,419.04% in Q2 2023, -8,906.06% for Q1 2023, and -10,797.62% during Q4 2022.